ALK e meccanismi di resistenza Lucio Crinò S.C. di Oncologia Medica Azienda Ospedaliera di Perugia Outline • Current evidence with ALK-TKIs in naïve patients • ALK-TKIs in crizotinib-refractory disease • Challenging brain mets in ALK+ disease • Resistance to crizotinib: focus on ‘unknown’ mechanisms Outline • Current evidence with ALK-TKIs in naïve patients • ALK-TKIs in crizotinib-refractory disease • Challenging brain mets in ALK+ disease • Resistance to crizotinib: focus on ‘unknown’ mechanisms Crizotinib for ALK+ advanced NSCLC: RR appr. 60%, PFS 7.7-9.7 mos Study No. of patients RR (%) PFS (mos.) A8081001 143 60.8 9.7 A8081005 261 59.8∞ 8.1 A8081007 173 65* 7.7 French Temporary Authorization for use of Crizotinib 230 56.5 Not reported ∞259 pts evaluable for response *Independent radiologic review Camidge, et al. Lancet Oncol 2012 Kim, et al. ASCO 2012 Shaw, et al. NEJM 2013 Perol, et al. ECCO 2013 [TITLE] Presented By Fabrice Barlesi, MD, PhD at 2013 ASCO Annual Meeting Efficacy and safety data Mean dura on of treatment (n=227): 5.01 months (range: 0.03 – 21.80) Radiological evalua on of response (physician assessment, RECIST 1.1) for 197 evaluable pa ents All pa ents N=197, % ECOG PS≥3 N=6, % Brain metastases N=58, % ≥3 previous treatment lines N=54, % Complete response 5.6% 0 3.5% 5.5% Par al response 59.3% 66.6% 67.2% 55.6% 64.9% 66.6% 70.7% 61.1% Stable disease 19.3% 16.7% 13.8% 12.9% Disease progression 15.7% 16.7% 15.5% 25.9% ORR (95%CI) Safety: 412 AEs related to crizo nib, of which 132 were SAEs, reported in 152 pts (49% of pts). Most frequent AEs were transaminases increase (10.0%), vision disorders (9.7%), neutropenia (5.3%), diarrhea (4.7%), peripheral oedema (4.9%), asthenia (4.1%) and nausea (3.9%). Conclusion: ac vity and safety profile of crizo nib are similar in clinical prac ce to those of clinical trials (PROFILE 1001, 1005 and 1007) with a good benefit/toxicity ra o. 2nd generation ALK-inhibitors in clinical development Drug Inhibition of secondary L1196M ‘gatekeeper’ mutation Company Clinical stage AP-26113 Yes Ariad Pharmaceuticals Phase I/II LDK378 Yes Novartis Phase II/III Alectinib Yes Chugai Pharmaceuticals Phase I/II TSR-011 Yes Tesaro Phase I NMS-E628 Yes Nerviano Medical Phase I ASP-3026 Yes Astellas Phase I X-376 and -396 Yes Xcovery Phase I CEP-28122 Yes Cephalon Preclinical RR with 2nd generation ALK-inhibitors in Crizotinib-naïve patients Author Drug No. of pts RR (%) Camidge (ECCO 2013) AP26113* 3 100 Shaw (ASCO 2013) LDK378** 35 60 Seto (Lancet Oncol 2013) Alectinib*** 46 93.5 *60-300 mg/d **400-750 mg/d ***300 mg x 2/d; Asiatic (Japanese) patients Outline • Current evidence with ALK-TKIs in naïve patients • ALK-TKIs in crizotinib-refractory disease • Challenging brain mets in ALK+ disease • Resistance to crizotinib: focus on ‘unknown’ mechanisms CHEMOTHERAPY TKI beyond PD or 2nd generation TKI ± local therapy TKI beyond PD + brain RT Chemotherapy +/- ongoing crizotinib for acquired resistance in ALK-positive NSCLC SWOG 1300 (in development) PI: Ross Camidge ALK rearrangement Progression on Crizotinib after response or SD > 3 mo No prior pemetrexed N=114 Co-primary endpoint: progression-free survival Respnse rate, pemetrexed alone R A N D O M I Z E Pemetrexed alone Pemetrexed + ongoing Crizotinib Crizotinib beyond progression Ou, et al. IASLC 2013 AP26113 in ALK+ NSCLCs (N=34) Best Change from Baseline in Target Lesion (%) Best Overall Response: • 40 20 b Progressive Disease Stable Disease Partial Response Complete Response 65% (22/34) objective response rate (95% CI: 47-80%) • 61% (19/31) post-crizotinib (incl. 1 criz intolerant) • 100% (3/3) in TKI-naïve (incl. 1 CR) 0 -20 -40 a c b -60 a -80 -100 d • a Response duration 8+ to 40+ weeks • 14 confirmed, 4 awaiting confirmation, 4 not confirmed 13 All patients received prior crizotinib unless otherwise indicated; Doses ranged from 60-240 mg/d (23 pts ≥180mg/d); aTKI-naïve; bReceived prior crizotinib and LDK378; cPD by RECIST 1.1 due to 2nd primary tumor of melanoma; dCrizotinib-intolerant of 6 Sept2013 2013 Camidge, etData al.as IASLC Alectinib in crizotinib-refractory patients Overall RR 54.5% across all cohorts for all patients Waterfall plot % tumor shrinkage Duration on study Days on study (*: off study, data cut-off Sept. 12, 2013) ** * * * * ** ** * * * * Overall RR 59.5% for cohorts of 460 mg dose or higher 24 of the 47 patients received the drug for 120 days or longer Gadgeel, et al. IASLC 2013 Outline • Current evidence with ALK-TKIs in naïve patients • ALK-TKIs in crizotinib-refractory disease • Challenging brain mets in ALK+ disease • Resistance to crizotinib: focus on ‘unknown’ mechanisms The problem of CNS progression to Crizotinib in ALK+ patients • 13/28 (46%) patients at U. of Colorado with first progression in CNS 2/13 had synchronous systemic progression Weickardt et al. JTO 2013 • Decreased CSF:plasma (0.0026) ratio suggestive of pharmacological failure of Crizotinib Costa et al. JCO 2011 Crizotinib antitumour activity in patients with or without brain metastasis (BM) at baseline Previously untreated for BM (n=109) n Outcome Previously treated for BM (n=166) n Outcome No BM detected (n=613) n Outcome DCR at 12 weeks, % (95%CI) IC 109 56 (46−66) 166 62 (54−70) Systemic 109 63 (54−72) 166 65 (57−72) 109 7 (3−14) 166 7 (4−12) NA 22 18 (5−40) 18 33 (13−59) NA 109 53 (43−63) 166 46 (39−54) NA 613 71 (68−75) ORR, % (95% CI) IC Target-lesion BM Systemic 613 55 (51−59) Median time to tumor response (range),a weeks IC Systemic 8 6.0 (4.9−12.4) 12 6.4 (5.9−17.7) 58 6.1 (2.0−31.4) 77 6.1 (3.1−35.3) 8 26.4 (6.1−59.3) 12 NR (6.0−59.9) 58 47.9 (5.3−55.0) 77 55.6 (4.4−95.3) 336 49.0 (4.1−96.1) 109 8.3 (6.7−14.0) 166 13.5 (6.2−16.5) 613 9.9 (8.8−12.2) NA 336 6.1 (3.0−49.1) Median duration of responseb (range),a weeks IC Systemic Median systemic PFS,b (95% CI),c mo NR, not reached aIn patients with confirmed objective response; bKaplan−Meier method; cBrookmeyer−Crowley method NA Costa, et al. IASLC 2013 Example of a complete response of a brain lesion in response to crizotinib treatment Before initiation of crizotinib 6 weeks after crizotinib 250 mg BID This patient presented with a brain lesion previously treated with chemotherapy and palliative IC radiation, which was classified as a target lesion. A CR in this lesion was observed after 6 weeks of treatment and had persisted for 54 weeks by data cutoff (courtesy of J-Y Han, National Cancer Center, Goyang, South Korea) Systemic progression-free survival (PFS) by presence or absence of brain metastases (BM) at baseline (BL) The presence of BM at BL does not significantly affect systemic PFS to crizotinib Costa, et al. IASLC 2013 CNS activity of alectinib • ORR of the 21 patients as determined by central image review CR PR SD PD Total N=21 6 5 8 2 % 29% 24% 38% 10% • 9/21 patients with baseline CNS metastasis had measurable CNS lesions and received no prior radiation within 4 weeks from first dose of alectinib – No CR. 5/9 achieved CNS PR (≥ 30% reduction in sum of largest dimension). 2/9 had CNS stable disease and 2/9 had CNS progression. 0.60 PR 0.40 0.20 0.00 Brain RT > 4 wks 91+ 203+ No brain RT 42 -0.20 -0.40 224+ 287+ 224+ -0.60 98+ 196+ 294+ -0.80 Progressing CNS mets Days on study Ou, et al. IASLC 2013 Outline • Current evidence with ALK-TKIs in naïve patients • ALK-TKIs in crizotinib-refractory disease • Challenging brain mets in ALK+ disease • Resistance to crizotinib: focus on ‘unknown’ mechanisms Unraveling the mechanisms of resistance to EGFR-TKIs and Crizotinib Unknown ALK amp ALK+ ALK mut No ALK amp or mut Bypass tracks EGFR MT KRAS MT Katayama, et al. Sci Trans Med. 2012 Doebele, et al. Clin Cancer Res. 2012 IGF-1R and IRS-1 are up-regulated in ALK TKI resistant cells Generation of isogenic pairs of ALK TKI sensitive and ALK TKI resistant cells TKI sensitive ALK TKI [nM] pALK Y1604 ALK pIGF-1R Y1131 IGF-1R pAKT S473 AKT pS6 S6 pERK ERK IRS-1 pY941 References: Lovly, C et al 2011 Cancer Research and Lovly, C et al submitted IRS-1 TKI resistant pIGF-1R pIGF-1Rand andIRS-1 IRS-1are areup-regulated up-regulatedininpatient patientbiopsy biopsysamples samplesatat the thetime timeof ofacquired acquiredresistance resistanceto tocrizotinib crizotinib Reference: Lovly, C et al submitted IGF-1R inhibitors sensitize H3122 ALK TKI resistant cells to the anti-proliferative effects of ALK inhibitors Key: - X-376: ALK TKI - MAb391: IGF-1R MAb - Soft agar assay in H3122 X-376 resistant cells Similar results seen in H3122 crizotinib resistant cells Analogous results seen with IGF-1R TKIs in addition to IGF-1R MAbs Reference: Lovly, C et al submitted Rationale for double ALK/HSP90 inhibition in ALK+ advanced NSCLC From Crystal and Shaw, Clin Cancer Res 2012 Hsp90 inhibitor AUY922: activity in ALK+ patients (n=19/22) Felip, et al. ESMO 2012 The Hsp90i AT13387 overcomes acquired resistance to crizotinib H2228 tumor xenografts treated with crizotinib H2228R tumor xenografts treated with AT13387 Crizotinib 50 mg/kg po qd + cyclodextrin ip 1qw 500 1400 Tumor volume (mm3) 2 1000 3 800 4 600 5 400 6 Tumor #6 transplanted 400 300 200 100 7 200 Tumor volume (mm3) 1 1200 0 0 1 29 57 85 113 141 169 Continuous daily crizotinib treatment • Crizotinib 50 mg/kg po qd + AT13387 55 mg/kg ip 1qw 197 Day 1 8 15 22 Day 29 AT13387 treatment inhibits the growth of an ALK-dependent tumor xenograft with acquired resistance to crizotinib Wallis, IASLC 2013 Rationale for the upfront use of combination regimens Therapy Therapy Therapy Resistance Selection for resistance Selection for genetic instability ALK: (e.g. ALK-TKI + Hsp90 inhibitor; ALK-TKI + IGFR-1R inhibitors ) Preclinical evidence for UPFRONT dual ALK/Hsp90 inhibition: ALK-TKI + Ganetespib Sang et al. Cancer Discov 2013 Preclinical evidence for UPFRONT dual ALK/Hsp90 inhibition: ALK-TKI + AT13387 Final tumor weight (Day 126) 700 Tumor weight (m g) Vehicle (cyclodextrin) ip 1qw AT13387 55 mg/kg ip 1qw Crizotinib 50 mg/kg po qd Crizotinib 50 mg/kg po qd + AT13387 55 mg/kg ip 1qw 500 75 50 25 0 Crizotinib + AT13387 300 400 300 200 100 Crizotinib 250 Crizotinib+AT13387 200 150 100 50 0 0 1 • • 100 Crizotinib Relative Tumor Volume Tumor volume (mm3) 600 500 450 125 8 15 22 29 Day 36 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 Continuous treatment Day Combination of AT13387 and crizotinib shows improved inhibition of tumor growth over monotherapies Combining crizotinib upfront with AT13387 delays the emergence of resistance in vivo Wallis, IASLC 2013 Clinical attempt to better Crizotinib: trials of ALK/HSP90 inhibition Regimen Phase ClinicalTrials.gov Identifier Crizotinib + AT13387 I/II NCT01712217 Crizotinib + Ganetespib I/II NCT01579994 LDK378 + AUY922 Ib NCT01772797 ALK-inhibition in ALK+ NSCLC • Platform networks required tools for optimization of NSCLC treatment • 2nd generation ALK-TKIs may break the boundary of 60% response rate observed with Crizotinib • Appr. 60% of RR with 2nd generation ALK-TKIs in Crizotinibrefractory patients • 2nd generation ALK-TKIs may prevent CNS pharmacological failure • Hsp90 activity and IGF-1R upregulation may be partly responsible for the non-ALK dominant mechanisms of resistance to crizotinib • Robust preclinical evidence of anticancer efficacy with ALKTKIs + HSP90 or IGF-1R inhibitors in ALK+ advanced NSCLC Thanks for your attention lucio.crino@ospedale.perugia.it